The interplay between drug resistance and fitness in malaria parasites
about
Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant BacteriaAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkPolymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan ChildrenTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaEvolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole PhysiologyA potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologueThe effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataPlasmodium falciparum K13 Mutations Differentially Impact Ozonide Susceptibility and Parasite Fitness In Vitro.Assessment of copy number variation in genes related to drug resistance in Plasmodium vivax and Plasmodium falciparum isolates from the Brazilian Amazon and a systematic review of the literatureArtemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on Plasmodium Falciparum Drug Sensitivity-Associated Haplotypes in Uganda.Competition between Plasmodium falciparum strains in clinical infections during in vitro culture adaptationFunctional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes.Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda.In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine.PfMDR2 and PfMDR5 are dispensable for Plasmodium falciparum asexual parasite multiplication but change in vitro susceptibility to anti-malarial drugs.Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytesImpact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles.Genome-wide transcriptome profiling reveals functional networks involving the Plasmodium falciparum drug resistance transporters PfCRT and PfMDR1Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter.Fitness of artemisinin-resistant Plasmodium falciparum in vitro.Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial.Combinatorial Genetic Modeling of pfcrt-Mediated Drug Resistance Evolution in Plasmodium falciparum.Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisininAntimalarial Benzoxaboroles Target Plasmodium falciparum Leucyl-tRNA Synthetase.Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine in Ugandan Schoolchildren Selects for Plasmodium falciparum Transporter Polymorphisms That Modify Drug Sensitivity.Indels, structural variation, and recombination drive genomic diversity in Plasmodium falciparum.Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in UgandaEvolutionary consequences of drug resistance: shared principles across diverse targets and organisms.Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda.Epistasis and the Evolution of Antimicrobial Resistance.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.Comparative Prevalence of Plasmodium falciparum Resistance-Associated Genetic Polymorphisms in Parasites Infecting Humans and Mosquitoes in Uganda.Impact of intermittent preventive treatment during pregnancy on Plasmodium falciparum drug resistance-mediating polymorphisms in Uganda.Azithromycin for Malaria?malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication.Impacts of Antimalarial Drugs on Plasmodium falciparum Drug Resistance Markers, Western Kenya, 2003-2015.
P2860
Q26741585-621E7F20-FCC2-445F-A476-5474BF70E69CQ26799713-1D4D00D6-093B-43D8-9368-E2FD033BE8E7Q27861962-1DAED063-198C-4523-97C9-D56360562BCBQ28125904-199DB0A9-3FF3-41B8-B770-71CE465A0F9DQ28553454-2BD5021B-1484-4D2B-8A5D-C416846E34D3Q30045921-20167AD9-FC99-4546-94FA-03B1983D5405Q30936416-9D2CF430-072F-4EAC-948C-4219CE662466Q33555297-1A5C8F74-9C04-47DD-BD01-767506B32938Q33577218-F16424A7-781E-4CB9-A72E-BB1EE7E5CADEQ33629027-93041802-68E0-49D7-8212-5E2E8BA6DB7CQ33680865-45D603C8-670E-4C97-A5E4-D20161A89E98Q33902615-C6427C6B-012A-432A-94F3-084E0AD07820Q34169765-315DB9D4-4E6A-4E6F-9CF0-5C55FDA42753Q34438960-589120D2-C20C-4082-A4CA-11108B0DB8B1Q35149404-005DCD79-4F53-480F-8C82-B766EF774F01Q35356543-724A009B-3057-4871-B142-D9CDAB33CDCAQ35607727-E72F5CDB-7BFF-4B87-BD79-A033FA0B6D1DQ35607844-8AA8B55E-52CB-4CCE-8E8B-F4CF3E5B89DEQ35846426-88706907-8A08-4F58-98BF-A50CE50C495FQ35874266-AEF15812-EE25-4A12-B35E-82045FDF9EBBQ35879787-4997F6BD-8AFC-494D-B984-6F000FD1A9A3Q36344786-BA3C7DD0-302B-4FA6-AA68-F3FFB960064CQ36812874-7BA6B7AC-A345-4A90-8212-85E5379D8099Q36904205-684724FA-A5C9-4146-B20A-FB9FEB0E0AE4Q36919648-2A15C710-DB92-4BA2-96DF-111AC9832B57Q37119350-B28E4581-BF6F-457D-BC49-F2E5A859ECA9Q37120074-BC75A760-6044-4439-9251-DE285D806DA8Q37287899-20DA6E5A-B759-4341-AC26-DF4A26A7A242Q37313676-11FEF9AE-CBEF-4436-96CF-6F60ABE98EBDQ37538658-2F59E7BA-995C-4205-BF92-11C2AA977CFDQ37715709-52B48A7E-1F09-48E4-943A-F9170268FACAQ38543385-45E21EEC-33EA-4851-B582-E69BB7974B4DQ38851726-08CEC1D4-101B-4568-AAC0-51BEBD241FBDQ39162611-1F3FBD24-0FCA-4B5E-8C07-E480DA4FF6C7Q40106428-5F9F7091-D171-4D41-B5DC-B99AF964F4BDQ41989143-1C5ACF73-9FC4-4B7F-BF50-07E203DB5362Q41992238-E64845A0-9E77-4FA5-BCF0-ED6587D0D016Q42421033-7C403419-B930-43F3-857D-8CDB6A326D95Q47130457-9F0B7D97-F02B-43F6-8C0B-9639158145BEQ48023089-4B438A4C-7379-47EA-B82C-1D28385B6396
P2860
The interplay between drug resistance and fitness in malaria parasites
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The interplay between drug resistance and fitness in malaria parasites
@ast
The interplay between drug resistance and fitness in malaria parasites
@en
The interplay between drug resistance and fitness in malaria parasites
@nl
type
label
The interplay between drug resistance and fitness in malaria parasites
@ast
The interplay between drug resistance and fitness in malaria parasites
@en
The interplay between drug resistance and fitness in malaria parasites
@nl
prefLabel
The interplay between drug resistance and fitness in malaria parasites
@ast
The interplay between drug resistance and fitness in malaria parasites
@en
The interplay between drug resistance and fitness in malaria parasites
@nl
P2860
P3181
P356
P1476
The interplay between drug resistance and fitness in malaria parasites
@en
P2093
Philip J. Rosenthal
P2860
P304
P3181
P356
10.1111/MMI.12349
P407
P577
2013-09-01T00:00:00Z